Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Research & Development (2020 - 2025)

Historic Research & Development for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Bioventus' Research & Development fell 2393.96% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 1346.29%. This contributed to the annual value of $13.6 million for FY2024, which is 143.54% up from last year.
  • Bioventus' Research & Development amounted to $2.9 million in Q3 2025, which was down 2393.96% from $3.2 million recorded in Q2 2025.
  • Bioventus' 5-year Research & Development high stood at $7.1 million for Q4 2021, and its period low was $947000.0 during Q2 2021.
  • In the last 5 years, Bioventus' Research & Development had a median value of $3.8 million in 2023 and averaged $4.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 5587.14% in 2021, then soared by 63157.34% in 2022.
  • Over the past 5 years, Bioventus' Research & Development (Quarter) stood at $7.1 million in 2021, then decreased by 16.29% to $5.9 million in 2022, then plummeted by 45.14% to $3.3 million in 2023, then fell by 9.29% to $3.0 million in 2024, then fell by 1.22% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.2 million for Q2 2025, and $3.0 million during Q1 2025.